406 related articles for article (PubMed ID: 28646324)
1. Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.
Mistarz UH; Singh SK; Nguyen TTTN; Roeffen W; Yang F; Lissau C; Madsen SM; Vrang A; Tiendrebeogo RW; Kana IH; Sauerwein RW; Theisen M; Rand KD
Pharm Res; 2017 Sep; 34(9):1970-1983. PubMed ID: 28646324
[TBL] [Abstract][Full Text] [Related]
2. A Plasmodium falciparum 48/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies.
Singh SK; Roeffen W; Andersen G; Bousema T; Christiansen M; Sauerwein R; Theisen M
Vaccine; 2015 Apr; 33(16):1981-6. PubMed ID: 25728318
[TBL] [Abstract][Full Text] [Related]
3. Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants.
Roeffen W; Theisen M; van de Vegte-Bolmer M; van Gemert G; Arens T; Andersen G; Christiansen M; Sevargave L; Singh SK; Kaviraj S; Sauerwein R
Malar J; 2015 Nov; 14():443. PubMed ID: 26552428
[TBL] [Abstract][Full Text] [Related]
4. Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas.
Baptista BO; de Souza ABL; Riccio EKP; Bianco-Junior C; Totino PRR; Martins da Silva JH; Theisen M; Singh SK; Amoah LE; Ribeiro-Alves M; Souza RM; Lima-Junior JC; Daniel-Ribeiro CT; Pratt-Riccio LR
Malar J; 2022 Jan; 21(1):6. PubMed ID: 34983540
[TBL] [Abstract][Full Text] [Related]
5. Fusion to Tetrahymena thermophila granule lattice protein 1 confers solubility to sexual stage malaria antigens in Escherichia coli.
Agrawal A; Bisharyan Y; Papoyan A; Bednenko J; Cardarelli J; Yao M; Clark T; Berkmen M; Ke N; Colussi P
Protein Expr Purif; 2019 Jan; 153():7-17. PubMed ID: 30081196
[TBL] [Abstract][Full Text] [Related]
6. Construct design, production, and characterization of Plasmodium falciparum 48/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine.
Singh SK; Roeffen W; Mistarz UH; Chourasia BK; Yang F; Rand KD; Sauerwein RW; Theisen M
Microb Cell Fact; 2017 May; 16(1):97. PubMed ID: 28569168
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
[TBL] [Abstract][Full Text] [Related]
8. A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies.
Theisen M; Soe S; Brunstedt K; Follmann F; Bredmose L; Israelsen H; Madsen SM; Druilhe P
Vaccine; 2004 Mar; 22(9-10):1188-98. PubMed ID: 15003647
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children.
Bélard S; Issifou S; Hounkpatin AB; Schaumburg F; Ngoa UA; Esen M; Fendel R; de Salazar PM; Mürbeth RE; Milligan P; Imbault N; Imoukhuede EB; Theisen M; Jepsen S; Noor RA; Okech B; Kremsner PG; Mordmüller B
PLoS One; 2011; 6(7):e22525. PubMed ID: 21829466
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
11. The use of a P. falciparum specific coiled-coil domain to construct a self-assembling protein nanoparticle vaccine to prevent malaria.
Karch CP; Doll TAPF; Paulillo SM; Nebie I; Lanar DE; Corradin G; Burkhard P
J Nanobiotechnology; 2017 Sep; 15(1):62. PubMed ID: 28877692
[TBL] [Abstract][Full Text] [Related]
12. Antibody responses to two new Lactococcus lactis-produced recombinant Pfs48/45 and Pfs230 proteins increase with age in malaria patients living in the Central Region of Ghana.
Acquah FK; Obboh EK; Asare K; Boampong JN; Nuvor SV; Singh SK; Theisen M; Williamson KC; Amoah LE
Malar J; 2017 Aug; 16(1):306. PubMed ID: 28764709
[TBL] [Abstract][Full Text] [Related]
13. Humoral immune response to Plasmodium falciparum vaccine candidate GMZ2 and its components in populations naturally exposed to seasonal malaria in Ethiopia.
Mamo H; Esen M; Ajua A; Theisen M; Mordmüller B; Petros B
Malar J; 2013 Feb; 12():51. PubMed ID: 23383869
[TBL] [Abstract][Full Text] [Related]
14. Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen.
Baldwin SL; Roeffen W; Singh SK; Tiendrebeogo RW; Christiansen M; Beebe E; Carter D; Fox CB; Howard RF; Reed SG; Sauerwein R; Theisen M
Vaccine; 2016 Apr; 34(19):2207-15. PubMed ID: 26994314
[TBL] [Abstract][Full Text] [Related]
15. Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens.
Amoani B; Gyan B; Sakyi SA; Abu EK; Nuvor SV; Barnes P; Sarkodie-Addo T; Ahenkorah B; Sewor C; Dwomoh D; Theisen M; Cappello M; Wilson MD; Adu B
BMC Infect Dis; 2021 Apr; 21(1):332. PubMed ID: 33832450
[TBL] [Abstract][Full Text] [Related]
16. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine.
Theisen M; Jore MM; Sauerwein R
Expert Rev Vaccines; 2017 Apr; 16(4):329-336. PubMed ID: 28043178
[TBL] [Abstract][Full Text] [Related]
17. A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based
Singh SK; Plieskatt J; Chourasia BK; Fabra-García A; Garcia-Senosiain A; Singh V; Bengtsson KL; Reimer JM; Sauerwein R; Jore MM; Theisen M
Front Immunol; 2020; 11():606266. PubMed ID: 33505395
[TBL] [Abstract][Full Text] [Related]
18. Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.
Dejon-Agobe JC; Ateba-Ngoa U; Lalremruata A; Homoet A; Engelhorn J; Nouatin OP; Edoa JR; Fernandes JF; Esen M; Mouwenda YD; Betouke Ongwe EM; Massinga-Loembe M; Hoffman SL; Sim BKL; Theisen M; Kremsner PG; Adegnika AA; Lell B; Mordmüller B
Clin Infect Dis; 2019 Sep; 69(8):1377-1384. PubMed ID: 30561539
[TBL] [Abstract][Full Text] [Related]
19. Natural antibody responses to Plasmodium falciparum MSP3 and GLURP(R0) antigens are associated with low parasite densities in malaria patients living in the Central Region of Ghana.
Amoah LE; Nuvor SV; Obboh EK; Acquah FK; Asare K; Singh SK; Boampong JN; Theisen M; Williamson KC
Parasit Vectors; 2017 Aug; 10(1):395. PubMed ID: 28835262
[TBL] [Abstract][Full Text] [Related]
20. A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children.
Sirima SB; Mordmüller B; Milligan P; Ngoa UA; Kironde F; Atuguba F; Tiono AB; Issifou S; Kaddumukasa M; Bangre O; Flach C; Christiansen M; Bang P; Chilengi R; Jepsen S; Kremsner PG; Theisen M;
Vaccine; 2016 Aug; 34(38):4536-4542. PubMed ID: 27477844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]